Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment

被引:47
作者
Gillen, D
Wirz, AA
McColl, KEL [1 ]
机构
[1] Univ Glasgow, Dept Med & Therapeut, Glasgow, Lanark, Scotland
[2] Aberdeen Royal Infirm, GI Unit, Aberdeen, Scotland
关键词
D O I
10.1053/j.gastro.2004.01.004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Rebound increased acid secretion has been observed at 2 weeks after discontinuing omeprazole treatment in Helicobacter pylori-negative, but not H. pylori-positive, subjects. It is unknown whether this is a prolonged phenomenon or whether a similar phenomenon appears later in H. pylori positives or is released by eradication therapy. The aims of this study were to answer these 3 questions. Methods: Twelve H. pylori-negative and 20 H. pylori-positive subjects were studied. Each had a basal, submaximal, and maximal pentagastrin-stimulated acid secretion study before, during, and at 7, 14, 28, 42, and 56 days after a 56-day course of omeprazole 40 mg/day. Ten of the H. pylori-positive subjects had their infection eradicated during the last week of treatment. Results: In the H. pylorinegative subjects, there was rebound secretion of submaximal (P < 0.003) and maximal (P < 0.003) acid output, which persisted until at least 56 days after discontinuing omeprazole. The H. pylori-uneradicated subjects had no rebound increased secretion other than in maximal acid output at 28 (P < 0.01) and at 42 days after treatment (P < 0.02). In those eradicated of H. pylori close to the end of omeprazole, there was rebound increased secretion of submaximal acid output (P < 0.04) lasting until 56 days and of maximal acid output (P < 0.01) lasting until 28 days after treatment. Conclusions: Rebound increased acid secretion following orneprazole is a prolonged phenomenon in H. pylorinegative subjects. There is little evidence of it in H. pylori-infected subjects, but eradicating the infection releases the phenomenon. The accentuated H. pylorirelated oxyntic gastritis induced by orneprazole is likely to protect against the rebound phenomenon.
引用
收藏
页码:980 / 988
页数:9
相关论文
共 45 条
[1]  
[Anonymous], GASTROENTEROLOGY S
[2]   DEFINITION AND ANTAGONISM OF HISTAMINE H2-RECEPTORS [J].
BLACK, JW ;
PARSONS, EM ;
DURANT, CJ ;
DUNCAN, WAM ;
GANELLIN, CR .
NATURE, 1972, 236 (5347) :385-&
[3]   Multivariate analysis of pathophysiological factors in reflux oesophagitis [J].
Cadiot, G ;
Bruhat, A ;
Rigaud, D ;
Coste, T ;
Vuagnat, A ;
Benyedder, Y ;
Vallot, T ;
LeGuludec, D ;
Mignon, M .
GUT, 1997, 40 (02) :167-174
[4]  
CAVE DR, 1989, LANCET, V2, P187
[5]   IS HELICOBACTER-PYLORI ASSOCIATED HYPERGASTRINEMIA DUE TO THE BACTERIUMS UREASE ACTIVITY OR THE ANTRAL GASTRITIS [J].
CHITTAJALLU, RS ;
DORRIAN, CA ;
NEITHERCUT, WD ;
DAHILL, S ;
MCCOLL, KEL .
GUT, 1991, 32 (11) :1286-1290
[6]   EFFECT OF SHORT-TERM AND LONG-TERM FEEDING OF OMEPRAZOLE ON RAT GASTRIC ENDOCRINE-CELLS [J].
CREUTZFELDT, W ;
STOCKMANN, F ;
CONLON, JM ;
FOLSCH, UR ;
BONATZ, G ;
WULFRATH, M .
DIGESTION, 1986, 35 :84-97
[7]  
DRIMAN D, 1995, GASTROENTEROLOGY, V108, pA85
[8]   EFFECT OF GASTRIN RECEPTOR BLOCKADE ON ENDOCRINE-CELLS IN RATS DURING ACHLORHYDRIA [J].
EISSELE, R ;
PATBERG, H ;
KOOP, H ;
KRACK, W ;
LORENZ, W ;
MCKNIGHT, AT ;
ARNOLD, R .
GASTROENTEROLOGY, 1992, 103 (05) :1596-1601
[9]   Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia [J].
Eissele, R ;
Brunner, G ;
Simon, B ;
Solcia, E ;
Arnold, R .
GASTROENTEROLOGY, 1997, 112 (03) :707-717
[10]   Eradicating Helicobacter pylori reduces hypergastrinaemia during long term omeprazole treatment [J].
El-Nujumi, A ;
Williams, C ;
Ardill, JE ;
Oien, K ;
McColl, KEL .
GUT, 1998, 42 (02) :159-165